_256_384.jpg)
News | August 12, 2025
Briefs: Nectar Lifesciences, Cipla and Marksans Pharma
Marksans Pharma gets USFDA nod for acid reflux drug
Marksans Pharma gets USFDA nod for acid reflux drug
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Experts urge early detection & better access to care
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
